Clinical Research Details

Clinical Research

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk

Study Description

The purpose of the study is to show that efpeglenatide does not increase the risk of having a heart attack, stroke or death from a cardiovascular event. Efpeglenatide has been tested previously in approximately 720 humans and the results have shown a positive effect on glucose in the blood.


Principal Investigator
Joe M. Chehade, M.D.